Your session is about to expire
← Back to Search
Local Anesthetic
Adductor Canal Block for Pain Management After Knee Surgery
N/A
Waitlist Available
Led By Joseph Rinehart, MD
Research Sponsored by University of California, Irvine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up postoperative (while in pacu), an expected average of 60 minutes
Awards & highlights
Study Summary
This trial looks at whether a single shot of pain medication into the adductor canal block (ACB) can decrease pain scores in people who have recently had total knee arthroplasty (TKA).
Who is the study for?
This trial is for adults aged 18+ undergoing total knee arthroplasty who are generally healthy (American Society of Anesthesiologists status I to III). It's not for those with diabetic neuropathy, kidney or liver issues, pregnant or nursing women, children under 18, opioid-tolerant individuals, people allergic to local anesthetics, or with a BMI over 40.Check my eligibility
What is being tested?
The study tests if a single injection adductor canal block (ACB) can better manage pain after knee surgery. Participants will receive either saline as a control ACB or Ropivacaine for the actual ACB. Additionally, all participants get local infiltration with a mix including Ropivacaine and other drugs.See study design
What are the potential side effects?
Possible side effects include reactions at the injection site like pain and swelling. There might also be risks associated with nerve blocks such as weakness in the leg where injected. The mixture used could cause low blood pressure due to Epinephrine.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ postoperative (while in pacu), an expected average of 60 minutes
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~postoperative (while in pacu), an expected average of 60 minutes
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Pain
Secondary outcome measures
Average NRS Pain Score
Opioids
Length of Stay
+2 moreTrial Design
3Treatment groups
Experimental Treatment
Group I: ACB Study OnlyExperimental Treatment1 Intervention
ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block
Group II: ACB Study + Local infiltrationExperimental Treatment2 Interventions
ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block + Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
Group III: ACB Control + Local InfiltrationExperimental Treatment2 Interventions
ACB Control - 20 ml saline injection for ACB + Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
Find a Location
Who is running the clinical trial?
University of California, IrvineLead Sponsor
542 Previous Clinical Trials
1,921,946 Total Patients Enrolled
Joseph Rinehart, MDPrincipal InvestigatorUniversity of California, Irvine
Coral Sun, MDPrincipal InvestigatorUniversity of California, Irvine
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am under 18 years old.I am diabetic and have nerve damage in my hands or feet.I do not have active liver issues like hepatitis or jaundice.I take more than 30 mg of Morphine or its equivalent daily.I am 18 or older and having a total knee replacement at UCI Medical Center.You are allergic to local numbing medications.My kidney function is reduced.My health is good to moderately impaired according to anesthesia standards.Your body mass index (BMI) is higher than 40, which means you are severely overweight.
Research Study Groups:
This trial has the following groups:- Group 1: ACB Study Only
- Group 2: ACB Control + Local Infiltration
- Group 3: ACB Study + Local infiltration
Awards:
This trial has 3 awards, including:- Approved for 20 Other Conditions - This treatment demonstrated efficacy for 20 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger